Article
Engineering, Biomedical
Yixuan Guo, Yu Liu, Wei Wu, Daishun Ling, Qiao Zhang, Peng Zhao, Xi Hu
Summary: This article will discuss different types of IDO inhibitors and relevant clinical trials, especially feasible combined therapeutic modalities. In addition, it will also review cutting-edge nanomedicines that combine IDO inhibitors with other therapeutic modalities to effectively enhance the effectiveness of cancer therapy. Finally, the prospects of IDO inhibitors in clinical application and potential breakthroughs will be briefly discussed.
Article
Microbiology
Thiara Manuele Alves de Souza, Caroline Fernandes-Santos, Jessica Araujo da Paixao de Oliveira, Larissa Cristina Teixeira Tome, Victor Edgar Fiestas-Solorzano, Priscila Conrado Guerra Nunes, Gabriel Macedo Costa Guimaraes, Juan Camilo Sanchez-Arcila, Iury Amancio Paiva, Luis Jose de Souza, Paulo Vieira Damasco, Valber da Silva Frutuoso, Manoela Heringer, Luzia Maria De Oliveira-Pinto, Roberta Olmo Pinheiro, Flavia Barreto dos Santos, Elzinandes Leal de Azeredo
Summary: This study evaluated the activity of IDO-1 and the patterns of cytokines/chemokines in CHIKV patients. It was found that IDO-1 activity increased during the early acute phase of infection and decreased in the chronic phase. In the acute phase, concentrations of TNF-alpha, IL-6, IFN-gamma, CCL2/MCP-1, and CXCL10/IP-10 were increased. In the chronic phase, concentrations of CCL4/MIP-1 beta were increased, especially in patients with arthritis.
Review
Oncology
Yu Fujiwara, Shumei Kato, Mary K. Nesline, Jeffrey M. Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock
Summary: Strategies to overcome immunosuppression in the tumor microenvironment, such as IDO1 inhibition, have been explored to address resistance to immune checkpoint blockade. These strategies have shown promising results in preclinical studies and early-phase clinical trials. However, some clinical trials have yielded disappointing results, dampening enthusiasm for IDO inhibitors. Additional potential targets, such as the aryl hydrocarbon receptor and tryptophan 2,3-dioxygenase, have been proposed to enhance clinical effectiveness. The expression level of IDO1 varies among tumors and patients, highlighting the importance of patient selection based on IDO1 expression levels in clinical trials.
CANCER TREATMENT REVIEWS
(2022)
Review
Biochemistry & Molecular Biology
Pengbo Yang, Junhua Zhang
Summary: IDO1 is an enzyme involved in the conversion of tryptophan into kynurenine, playing a crucial role in various biological functions and cancer immunotherapy. Inhibiting IDO1 has potential therapeutic benefits for tumor treatment. Furthermore, IDO activity assays are valuable tools for screening and evaluating inhibitors.
Article
Cardiac & Cardiovascular Systems
Nattawut Wongpraparut, Ploy Pengchata, Sudarat Piyophirapong, Pariya Panchavinnin, Rungtiwa Pongakasira, Noppadol Arechep, Kanda Kasetsinsombat, Kittipong Maneechotesuwan
Summary: The study found that IDO, kynurenine, and hs-TnT levels were associated with the severity of CAD in patients. Patients with left main disease had higher 1-year mortality, and lower levels of IDO may predict an increased risk of mortality within one year.
BMC CARDIOVASCULAR DISORDERS
(2021)
Article
Biochemistry & Molecular Biology
Chenfei Zhou, Yanmei Zhang, Ruiming Yan, Lei Huang, Andrew L. Mellor, Yang Yang, Xiaojing Chen, Wenfei Wei, Xiangguang Wu, Lan Yu, Luojiao Liang, Dan Zhang, Sha Wu, Wei Wang
Summary: The high levels of miR-142-5p in advanced CSCC positively correlate with IDO expression in tumor-associated lymphatic vessels. The miR-142-5p is transferred by CSCC-secreted exosomes into LECs to induce IDO expression via ARID2-DNMT1-IFN-gamma signaling, leading to CD8(+)T cell exhaustion. This study suggests that LECs play a crucial role as immune checkpoints in the TME and may be a potential new target for CSCC diagnosis and treatment.
CELL DEATH AND DIFFERENTIATION
(2021)
Review
Chemistry, Medicinal
Frederike T. Fellendorf, Nina Bonkat, Nina Dalkner, Elena M. D. Schoenthaler, Mirko Manchia, Dietmar Fuchs, Eva Z. Reininghaus
Summary: This review highlights the inconsistent findings on KYN/TRP ratio in severe mental disorders. Although there are indications of inflammation associated with elevated IDO activity, no conclusive statements can be made. Considering factors such as inflammatory processes, metabolic activities, and psychological/neuropsychiatric symptoms are crucial for a deeper understanding of the underlying mechanisms.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Rahul Nandre, Vivek Verma, Pankaj Gaur, Veerupaxagouda Patil, Xingdong Yang, Zainab Ramlaoui, Nour Shobaki, Mads Hald Andersen, Ayako Wakatsuki Pedersen, Mai-Britt Zocca, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif
Summary: IDO+ cells in the immunosuppressive tumor microenvironment have stronger suppressive ability, and therapeutic approaches targeting these cells are needed.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Nirmalya Pradhan, Nasim Akhtar, Barnali Nath, Jorge Pena-Garcia, Anjali Gupta, Horacio Perez-Sanchez, Sachin Kumar, Debasis Manna
Summary: Quinine derivatives effectively inhibit the activity of IDO1 by competing with heme, providing a potential avenue for immunotherapy-based drug discovery strategies.
CHEMICAL COMMUNICATIONS
(2021)
Review
Oncology
Yu Yao, Heng Liang, Xin Fang, Shengnan Zhang, Zikang Xing, Lei Shi, Chunxiang Kuang, Barbara Seliger, Qing Yang
Summary: IDO1, a heme-containing enzyme, plays a crucial role in the kynurenine pathway of tryptophan metabolism, with implications in immunity and neuronal function. Despite potential applications in cancer and neurodegenerative diseases, cautionary notes from clinical trials indicate a need for better understanding of IDO1 inhibition mechanisms.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Wen Liu, Yi Zou, Kaiming Li, Haiqing Zhong, Longbo Yu, Shushan Ge, Yisheng Lai, Xianchi Dong, Qiang Xu, Wenjie Guo
Summary: Pharmacological inhibition of IDO1 has shown to be an effective approach for cancer treatment. However, existing inhibitors have limited response and unclear biomarkers in clinical practice. This study identified a potent inhibitor, B37, which targets apo-IDO1 and has strong antitumor efficacy by activating the host immune system.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Cristina C. Clement, Angelo D'Alessandro, Sangeetha Thangaswamy, Samantha Chalmers, Raquel Furtado, Sheila Spada, Giada Mondanelli, Federica Ianni, Sarah Gehrke, Marco Gargaro, Giorgia Manni, Luisa Carlota Lopez Cara, Peter Runge, Wanxia Li Tsai, Sinem Karaman, Jorge Arasa, Ruben Fernandez-Rodriguez, Amanda Beck, Antonio Macchiarulo, Massimo Gadina, Cornelia Halin, Francesca Fallarino, Mihaela Skobe, Marc Veldhoen, Simone Moretti, Silvia Formenti, Sandra Demaria, Rajesh K. Soni, Roberta Galarini, Roccaldo Sardella, Gregoire Lauvau, Chaim Putterman, Kari Alitalo, Ursula Grohmann, Laura Santambrogio
Summary: 3-hydroxy-L-kynurenamine (3-HKA) is a metabolite deriving from a lateral pathway of tryptophan catabolism. The authors identify 3-HKA as a biogenic amine with anti-inflammatory properties, showing its protective effects against psoriasis and nephrotoxic nephritis in mice.
NATURE COMMUNICATIONS
(2021)
Review
Medicine, Research & Experimental
Eslam E. Abd El-Fattah
Summary: Cancer is a leading cause of death globally. The change in the tumor immune microenvironment, specifically immunosuppression, is associated with cancer progression, metastasis, recurrence, and chemoresistance. Indoleamine 2,3-dioxygenase (IDO) and its metabolite kynurenine (Kyn) play a significant role in the immunosuppression of lung cancer.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Hongmei Liu, Huan Gao, Cheng Chen, Wenyu Jia, Delong Xu, Guan Jiang
Summary: In this study, a molecule called GM composed of IDO inhibitor 1MT and gallic acid GA was synthesized and found to have therapeutic effects on B16F10 melanoma cells and a mouse model. GM increased the solubility of 1MT, enhanced drug efficacy, and inhibited melanoma growth while regulating immune response.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hyun-Joo Lee, Harry Jung, Dong-Kyu Kim
Summary: Activated T-MSCs expressing IDO and CD40 have the capacity to inhibit immune cell proliferation and cytokine production, thereby modulating immune responses through Th1 and Th2 pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Genetics & Heredity
Aili Tagoma, Kristi Alnek, Anne Kirss, Raivo Uibo, Kadri Haller-Kikkatalo
Article
Biochemical Research Methods
Marina Sunina, Epp Kaleviste, Raivo Uibo, Kai Kisand
Article
Microbiology
Tommi Vatanen, Damian R. Plichta, Juhi Somani, Philipp C. Muench, Timothy D. Arthur, Andrew Brantley Hall, Sabine Rudolf, Edward J. Oakeley, Xiaobo Ke, Rachel A. Young, Henry J. Haiser, Raivo Kolde, Moran Yassour, Kristiina Luopajarvi, Heli Siljander, Suvi M. Virtanen, Jorma Ilonen, Raivo Uibo, Vallo Tillmann, Sergei Mokurov, Natalya Dorshakova, Jeffrey A. Porter, Alice C. McHardy, Harri Lahdesmaki, Hera Vlamakis, Curtis Huttenhower, Mikael Knip, Ramnik J. Xavier
NATURE MICROBIOLOGY
(2019)
Article
Pediatrics
Kart Simre, Oivi Uibo, Aleksandr Peet, Leena Puustinen, Sami Oikarainen, Kirsi Tamminen, Vesna Blazevic, Vallo Tillmann, Anu-Maaria Hamalainen, Taina Harkonen, Heli Siljander, Suvi M. Virtanen, Jorma Ilonen, Heikki Hyoty, Mikael Knip, Raivo Uibo
Article
Medical Laboratory Technology
Erik Orro, Kristi Alnek, Tiia Reimand, Koit Reimand, Oivi Uibo, Tiina Talvik, Kadri Haller-Kikkataloa, Kalle Kisand, Raivo Uibo
CLINICA CHIMICA ACTA
(2019)
Correction
Microbiology
Tommi Vatanen, Damian R. Plichta, Juhi Somani, Philipp C. Munch, Timothy D. Arthur, Andrew Brantley Hall, Sabine Rudolf, Edward J. Oakeley, Xiaobo Ke, Rachel A. Young, Henry J. Haiser, Raivo Kolde, Moran Yassour, Kristiina Luopajarvi, Heli Siljander, Suvi M. Virtanen, Jorma Ilonen, Raivo Uibo, Vallo Tillmann, Sergei Mokurov, Natalya Dorshakova, Jeffrey A. Porter, Alice C. McHardy, Harri Lahdesmaki, Hera Vlamakis, Curtis Huttenhower, Mikael Knip, Ramnik J. Xavier
NATURE MICROBIOLOGY
(2019)
Article
Immunology
Tamara Vorobjova, Aili Tagoma, Astrid Oras, Kristi Alnek, Kalle Kisand, Ija Talja, Oivi Uibo, Raivo Uibo
JOURNAL OF IMMUNOLOGY RESEARCH
(2019)
Article
Immunology
A. Oras, A. Peet, T. Giese, V. Tillmann, R. Uibo
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2019)
Article
Immunology
Marina Sunina, Kristi Alnek, Kai Kisand, Raivo Uibo
Summary: This study showed that in healthy blood donors, most T cells did not express CD226 and TIGIT before and after stimulation, instead predominantly upregulating activating receptors post-stimulation. Memory CD4(+) T cells displayed a balance of activating and inhibitory receptor expression before and after stimulation, while memory CD8(+) T cells predominantly expressed TIGIT. The rs763361 TT genotype was associated with reduced CD226 expression on CD4(+) memory T cells and increased interleukin-17A secretion from activated T cells.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Endocrinology & Metabolism
Aili Tagoma, Kadri Haller-Kikkatalo, Astrid Oras, Kristine Roos, Anne Kirss, Raivo Uibo
Summary: This study found that plasma adiponectin and CCL2 concentrations can distinguish women with GDM, and IL-27 and IL-22 levels may be associated with autoimmune reactions.
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Biotechnology & Applied Microbiology
Kristi Alnek, Ija Talja, Brita Laht, Kaja Metskuela, Maire Mandel, Ingrid Reppo, Maire Lubi, Raivo Uibo
Summary: This study found a significant association between enterovirus antibodies and type 1 diabetes in both children and young adults, suggesting that enterovirus infections may be an important disease-promoting factor. However, further virological studies are needed to confirm this association.
BIOMED RESEARCH INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Efe Ergur, Ege Ergur, Kristi Alnek, Kaja Metskula, Aleksandr Peet, Maire Lubi, Kaire Heilman, Raivo Uibo
Summary: The distribution of TCF7L2 polymorphism was assessed and associations between TCF7L2 and characteristics of type 1 diabetes were explored. The study found that TCF7L2 polymorphism is associated with zinc transporter 8 and islet antigen-2 autoantibodies and C-peptide levels in patients with type 1 diabetes.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Article
Multidisciplinary Sciences
Astrid Oras, Henna Kallionpa, Tomi Suomi, Satu Koskinen, Asta Laiho, Laura L. Elo, Mikael Knip, Riitta Lahesmaa, Alar Aints, Raivo Uibo
Summary: A study on the gene expression in B-cells from children developing CoD early in life revealed gene expression changes associated with CoD development, indicating the important role of B-cells in CoD development.
Article
Endocrinology & Metabolism
Tamara Vorobjova, Aili Tagoma, Ija Talja, Helis Janson, Anne Kirss, Raivo Uibo
Summary: This study aimed to compare FABP4 and I-FABP levels in pregnant women with GDM and healthy pregnant controls, and to investigate their relationship with BMI, enterovirus exposure, and adipokines. The results showed that FABP4 and I-FABP levels were not associated with the diagnosis of GDM, but rather with BMI. In women with GDM, I-FABP was positively correlated with adiponectin and resistin levels.
JOURNAL OF DIABETES RESEARCH
(2022)